Drug Profile
ZSP 1273
Alternative Names: ZSP-1273Latest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator Guangdong Zhongsheng Pharmaceutical
- Class Antivirals; Small molecules; Urologics
- Mechanism of Action DNA-directed RNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Influenza A virus infections
- Phase I Influenza virus infections; Kidney disorders
Most Recent Events
- 15 Jan 2024 Phase-I clinical trials in Kidney disorders (In adolescents, In adults, In the elderly) in China (PO) (NCT06248567)
- 22 Dec 2023 Guangdong Raynovent Biotech completes phase-I bioavailability trial (In volunteers) in China (PO, Tablet and Granule) (NCT06164431)
- 30 Nov 2023 Guangdong Raynovent Biotech completes phase-I pharmacokinetics trial (In volunteers) in China (PO) (NCT05954624)